Vanguard Capital Management
PLRX icon

Vanguard Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Vanguard Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
2,440,351
+97,250
+4% +$118K ﹤0.01% 3310
2026
Q1 		$2.95M Buy
+2,343,101
New +$2.96M ﹤0.01% 3242

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Vanguard Capital Management's PLRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Pliant Therapeutics (PLRX) stake by 4.2% in Q2 2026, buying an estimated $118K and bringing the position to 2,440,351 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

Vanguard Capital Management first reported a position in PLRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.95M in Q1 2026. 85 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Vanguard Capital Management held 2,440,351 shares of Pliant Therapeutics worth $2.78M as of Q2 2026.
  • Vanguard Capital Management bought 97,250 Pliant Therapeutics shares in Q2 2026, an estimated $118K.
  • Pliant Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3310 holding.
  • Vanguard Capital Management first reported a position in Pliant Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Pliant Therapeutics position peaked at $2.95M in Q1 2026.
  • 85 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.